Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

NEW YORK – The US Food and Drug Administration has cleared Aro Biotherapeutics' investigational new drug application for a short-interfering RNA (siRNA) drug it's developing for late-onset Pompe ...

NEW YORK – Viracta Therapeutics on Wednesday shuttered and laid off all employees. The financially beleaguered San Diego-based company last fall laid off 42 percent of its employees and reduced the ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

NEW YORK – Currently available large language models (LLMs) are not accurate enough to use safely for clinical decision support, but physician-scientists are continuing to test artificial intelligence ...